ABL1 and acute lymphoblastic leukemia: For instance, the addition of tyrosine kinase inhibitors (TKIs) to chemotherapy has markedly improved the clinical outcomes for children with Philadelphia chromosome-positive (Ph+) ALL and is now standard in care, and, additionally, clinical trial efforts are ongoing to credit TKI-based therapy for patients with BCR::ABL1-like/Philadelphia-like (Ph-like) ALL [17,18].